Aprea Therapeutics

APRE · NASDAQ

$0.5612+$0.0289 (+5.43%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.5323

APRE analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $3.81 (+578.5% upside)

Low: $1.21
Now: $0.5612
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

APRE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ladenburg Thalmann	Oct 14, 2026	Initiates	Buy	$2.00	40%
Wedbush	Aug 13, 2026	Maintains	Outperform	$6.00 → $3.00	39%
Wedbush	May 14, 2026	Maintains	Outperform	$7.00 → $6.00	39%
Oppenheimer	May 7, 2026	Initiates	Outperform	$5.00	35%
Wedbush	Mar 31, 2026	Maintains	Outperform	$7.00	39%
HC Wainwright & Co.	Mar 31, 2026	Maintains	Buy	$4.00 → $1.20	40%
Wedbush	Feb 10, 2026	Maintains	Outperform	$11.00 → $7.00	39%
HC Wainwright & Co.	Jan 29, 2026	Maintains	Buy	$5.00 → $4.00	40%
HC Wainwright & Co.	Dec 18, 2025	Maintains	Buy	$20.00 → $5.00	40%

The case for and against

Updated Sep 30, 2026

Bull case

Aprea Therapeutics is a clinical-stage precision medicine oncology company with a promising pipeline of small molecule inhibitors. With its focus on exploiting genetic mutations in cancer, the company has potential for success in the highly competitive cancer therapeutics market. However, there are risks to achieving the price target and rating, including the potential for clinical and regulatory failure of their lead candidate ATRN-119 and potential competition from other current and future therapies.

Bear case

Aprea Therapeutics is a clinical-stage precision medicine oncology company that is currently facing several challenges. So far, its clinical and preclinical programs have not shown significant results, despite promising mechanisms. The company also has a relatively short cash runway, which may put a strain on its operations in the near future. Additionally, the market for precision medicine oncology is highly competitive and Aprea Therapeutics must successfully navigate this landscape in order to be successful in the long term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.